plexidflu
assay
recent
develop
enabl
detect
type
influenza
virus
base
rtpcrelectrospray
ioniz
mass
spectrometri
technolog
novel
assay
evalu
type
perform
posit
influenza
b
nasopharyng
swab
specimen
np
detect
realtim
rtpcr
season
plexidflu
assay
detect
character
influenza
b
sampl
respect
nontyp
influenza
b
specimen
assay
show
low
viral
load
threshold
cycl
valu
taken
togeth
although
result
need
confirm
prospect
studi
plexidflu
assay
detect
posit
gave
type
result
np
detect
posit
realtim
rtpcr
thu
suggest
potenti
role
influenza
viru
surveil
among
techniqu
world
health
organ
global
influenza
surveil
respons
system
provid
essenti
inform
type
variant
influenza
virus
circul
worldwid
direct
detect
identif
influenza
strain
clinic
sampl
mostli
perform
use
specif
realtim
pcr
assay
less
frequent
culturebas
method
genotyp
phenotyp
character
posit
case
perform
sequenc
classic
pcr
amplicon
requir
multipl
primer
pair
follow
phylogenet
analysi
hemagglutinin
inhibit
assay
respect
influenza
pdm
pandem
result
develop
number
assay
singlemultiplex
realtim
rtpcr
microarray
system
allow
rapid
detect
type
influenza
viru
human
specimen
sensit
rapid
diagnost
type
assay
essenti
appropri
patient
manag
particularli
high
risk
patient
use
appropri
antivir
therapi
rtpcrelectrospray
ioniz
mass
spectrometri
esim
assay
develop
recent
enabl
potenti
detect
type
microbi
agent
includ
influenza
flow
procedur
technolog
reli
analysi
nucleotid
base
address
correspond
author
laboratori
virolog
divis
infecti
diseas
univers
geneva
hospit
rue
gabrielleperretgentil
geneva
switzerland
tel
fax
email
samuelcordey
hcugech
composit
signatur
highli
variabl
select
region
base
measur
molecular
weight
pcr
amplicon
first
version
influenza
assay
abbott
molecular
de
plain
il
usa
perform
instrument
ibisabbott
carlsbad
ca
usa
valid
influenza
includ
b
isol
collect
sensit
specif
estim
reach
respect
esim
analysi
also
capabl
identifi
viral
reassort
coinfect
ie
mix
popul
recent
assay
report
sensit
specif
respect
pdm
detect
sinc
assay
redesign
updat
plexidflu
assay
includ
one
paninfluenza
primer
set
target
segment
five
paninfluenzaa
primer
pair
target
individu
np
pa
gene
one
paninfluenza
b
primer
pair
target
segment
two
addit
primer
pair
target
two
surfac
antigen
ha
na
gene
plexid
platform
use
perform
pilot
evalu
detect
subtyp
lineag
character
human
influenza
viru
type
b
respect
nasopharyng
swab
specimen
np
collect
network
practition
particip
activ
clinic
surveil
influenza
case
switzerland
screen
influenza
season
use
follow
viral
genom
extract
use
nuclisen
easymag
geneva
switzerland
follow
four
onestep
realtim
rtpcr
assay
appli
routin
screen
cdc
paninfluenza
specif
realtim
rtpcr
assay
consid
refer
assay
influenza
type
surveil
three
inhous
develop
assay
specif
pdm
swine
ge
influenza
influenza
b
infb
mp
detect
supplementari
tabl
valid
qualiti
control
week
batch
influenzaposit
specimen
accord
number
avail
specimen
test
plexidflu
assay
parallel
usual
realtim
rtpcr
assay
perform
swiss
nation
refer
centr
influenza
np
select
blind
realtim
rtpcr
threshold
cycl
c
valu
type
influenza
influenza
b
assay
specif
posit
neg
intern
control
includ
systemat
run
rule
potenti
pcr
inhibitor
contamin
respect
strain
respect
note
plexidflu
assay
subtyp
lineag
character
type
b
specimen
respect
less
accur
pdm
specimen
sinc
ha
na
gene
includ
analysi
taken
togeth
plexidflu
assay
detect
posit
gave
typinglineag
character
result
np
detect
posit
realtim
rtpcr
posit
result
obtain
method
alway
agreement
nontyp
influenza
b
specimen
plexidflu
assay
show
rel
low
viral
load
c
valu
obtain
screen
realtim
rtpcr
assay
type
perform
plexidflu
assay
versu
sangerbas
sequenc
method
compar
influenza
specimen
low
viral
load
c
valu
influenza
influenza
bposit
np
tabl
briefli
sangerbas
sequenc
method
revers
transcript
perform
presenc
primer
updat
respect
provid
prof
rod
daniel
mrc
london
part
influenza
gene
amplifi
follow
influenza
virus
first
pcr
reaction
perform
primer
follow
two
nest
pcr
reaction
primer
pair
supplementari
tabl
influenza
b
virus
primer
use
first
pcr
reaction
follow
nest
pcr
use
primer
pair
sequenc
perform
abi
prism
dna
sequenc
appli
biosystem
rotkreuz
switzerland
analyz
geneiou
program
biomatt
auckland
new
zealand
neg
control
use
comparison
mark
nd
done
among
specimen
plexidflu
assay
abl
subtyp
influenza
character
lineag
influenza
b
sangerbas
sequenc
method
abl
subtyp
influenza
identifi
lineag
influenza
b
therefor
select
specimen
plexidflu
assay
demonstr
sensit
influenza
b
viru
lineag
character
least
similar
sangerbas
method
directli
depend
condit
use
viral
genom
amplif
classic
pcr
howev
latter
appear
sensit
influenza
subtyp
condit
observ
explain
plexidflu
assay
algorithm
requir
analysi
nucleotid
base
composit
signatur
minimum
three
posit
pcr
eight
independ
primer
pair
present
assay
mandatori
coupl
detect
subtyp
process
influenza
specimen
analysi
therefor
type
constraint
plexidflu
assay
explain
partial
higher
influenza
subtyp
perform
sangerbas
method
low
viral
load
specimen
inde
influenza
np
detect
posit
realtim
rtpcr
could
subtyp
plexidflu
assay
although
one
two
posit
pcr
signal
observ
although
minim
requir
three
independ
pcr
signal
subtyp
obtain
specif
influenza
pcr
amplif
detect
suggest
sensit
threshold
close
realtim
rtpcr
base
select
posit
np
collect
switzerland
influenza
season
studi
suggest
plexidflu
assay
conveni
platform
detect
type
subtyp
lineag
character
influenza
b
circul
influenza
virus
detect
rate
observ
plexid
platform
well
subtyp
lineag
character
human
influenza
viru
type
b
tend
suggest
might
play
role
near
futur
routin
laboratori
need
confirm
prospect
larg
compar
studi
addit
sensit
plexidflu
observ
studi
could
increas
posit
pcr
result
consid
type
result
requir
howev
pilot
studi
intrins
limit
mainli
relat
fact
realtim
rtpcrposit
specimen
select
initi
preclud
appropri
evalu
respect
sensit
specif
method
compar
sequenc
analysi
plexidflu
assay
also
limit
term
identif
specif
mutat
potenti
involv
antivir
resist
well
drift
strain
final
lack
accur
type
concern
ha
na
gene
major
drawback
possibl
limit
use
assay
first
line
diagnost
test
